Vident Advisory’s Labcorp LH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.5M Buy
41,118
+12,021
+41% +$3.16M 0.08% 220
2026
Q1
$7.76M Buy
29,097
+7,136
+32% +$1.93M 0.07% 251
2025
Q4
$5.51M Buy
21,961
+4,232
+24% +$1.12M 0.05% 304
2025
Q3
$5.09M Buy
17,729
+5,081
+40% +$1.36M 0.05% 305
2025
Q2
$3.32M Buy
12,648
+10,427
+469% +$2.54M 0.04% 369
2025
Q1
$517K Buy
2,221
+744
+50% +$181K 0.01% 1015
2024
Q4
$339K Sell
1,477
-4
-0.3% -$918 0.01% 1126
2024
Q3
$331K Sell
1,481
-15,859
-91% -$3.49M 0.01% 1100
2024
Q2
$3.53M Buy
17,340
+16,179
+1,394% +$3.29M 0.1% 214
2024
Q1
$254K Buy
1,161
+59
+5% +$13K 0.01% 1108
2023
Q4
$250K Sell
1,102
-47,426
-98% -$9.96M 0.01% 1099
2023
Q3
$9.76M Buy
+48,528
New +$10.2M 0.3% 99

Other funds holding LH

Vident Advisory's LH Position: Q2 2026 in Review

Vident Advisory increased its Labcorp (LH) stake by 41% in Q2 2026, buying an estimated $3.16M and bringing the position to 41,118 shares worth $11.5M. The position accounts for 0.08% of the portfolio, ranked #220.

Vident Advisory first reported a position in LH in Q3 2023 and has held it in 12 quarters since. 1,060 funds tracked by Wall St. Rank hold LH as of Q2 2026.

  • Vident Advisory held 41,118 shares of Labcorp worth $11.5M as of Q2 2026.
  • Vident Advisory bought 12,021 Labcorp shares in Q2 2026, an estimated $3.16M.
  • Labcorp made up 0.08% of Vident Advisory's portfolio in Q2 2026, its #220 holding.
  • Vident Advisory first reported a position in Labcorp in Q3 2023 and has held it in 12 quarters since.
  • 1,060 funds tracked by Wall St. Rank held Labcorp as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.